The project is aimed at reducing shortages of transplanted livers and liver organ rejection in people with acute liver failure. The award is in collaboration with Carnegie Mellon University, which will be leading this project team for the ARPA-H Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program. PRINT focuses on restoring normal tissue function, serving as a bridge to transplantation. The initiative combines expertise in bioprinting technology with a regenerative medicine approach to 3D print organs on demand, eliminating the need for immunosuppressive drugs. Through the Liver Immunocompetent Volumetric Engineering (LIVE) project, Mayo Clinic will help develop the standardization of mass-producing, phase-appropriate, current Good Manufacturing Practice (cGMP-ready) cell manufacturing. It also will oversee quality assurance as well as manage the Food and Drug Administration interactions needed to bring LIVE technology into clinical practice.

—Please visit https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-collaborates-on-arpa-h-award-to-develop-a-bioprinted-liver-for-acute-liver-failure/ to read more.